Because secondary brain injury is caused by multiple cascades of biochemical reactions, previous attempts using a single biochemical mechanism have all failed. With over thirty Phase III studies to date demonstrating the difficulty in stopping the biochemical cascade using the one-dimensional approach, intervention must address several pathways, both simultaneously and sequentially, to be effective.
The Company has designed several chemically verified proprietary NCEs (New Chemical Entities), each with lipophilic properties for crossing the blood-brain-barrier (BBB), and each with at least two of the following neuro-protective functions: free metal ion binding, anti-oxidation, and anti-inflammatory action.
In order to create these compounds, novel chemical spacers were invented by Dr. Adrian Harel. These spacers allow for the construction of complex compounds. These unique chemical spacers allow Medicortex to create medication that has the potential ability to stop the post-TBI cascade. The NCEs designed by Medicortex are patent protected, increasing the chances of financial success.
Currently focusing on the TBI biomarker R&D project